Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics & Biomarkers

Status Recruiting

Clinical Trial Summary

Dementia with Lewy Bodies (DLB) is an alphasynucleinopathy and the second most common form of dementia in the elderly. DLB shares striking neuropathological and clinical similarities with both Parkinson's disease (PD) and Alzheimer's disease (AD). Nilotinib (Tasigna®, AMN107, Novartis, Switzerland) is approved by the FDA and is well tolerated for CML treatment at oral doses of 600-800mg daily. The Investigators propose to perform a phase II randomized, double blinded, placebo controlled study to evaluate the impact of Nilotinib in patients with DLB.

Clinical Trial Description

A phase II randomized, double blinded, placebo controlled study will be performed to evaluate the impact of Nilotinib (Tasigna®, AMN107, Novartis, Switzerland) on safety, tolerability, pharmacokinetics, pharmacodynamics and clinical outcomes in patients with Dementia with Lewy Bodies. Sixty ( 60) participants will be recruited and randomly assigned 1:1 to placebo (arm 1) or 200 mg Nilotinib (arm 2).This study will be conducted in DLB patients with 2.5≥Hoehn & Yahr≤3 and UPDRS I-III ≤50 and 15≥UPDRS III (motor) ≥40 (Unified Parkinson's Disease Rating Score)and MoCA≥18(Montreal Cognitive Assessment). Eligible participants must be stable on MAO-B inhibitors (Rasageline or Selegeline) for 4 weeks and must not be on ≥800mg Levodopa daily. Participants must be stable on acetylcholinesterase inhibitors and other medications for at least 6 weeks. Participants will be treated for 6 months and monitored every month ( 4 weeks) in a total of 9 visits that include screening , baseline, 1, 2, 3, 4, 5, 6 months follow up and 7 month washout. Blood and cerebrospinal fluid (CSF) will be collected at baseline and at 6 months to determine Nilotinib effects on CSF biomarkers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04002674
Study type	Interventional
Source	Georgetown University
Contact	Myrna J Arellano, RN
Phone	(202)-444-7273
Email	mja6@gunet.georgetown.edu
Status	Recruiting
Phase	Phase 2
Start date	July 1, 2019
Completion date	December 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03996460` - K0706 for Patients Diagnosed With Dementia With Lewy Bodies	Phase 2
Recruiting	`NCT04335994` - ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing	N/A
Recruiting	`NCT02194816` - Modifiable Variables in Parkinsonism (MVP)
Active, not recruiting	`NCT01208675` - The Swedish BioFINDER Study
Completed	`NCT03538522` - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831	Phase 2
Recruiting	`NCT03672448` - The China Longitudinal Aging Study of Cognitive Impairment
Completed	`NCT01340001` - Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies	N/A
Not yet recruiting	`NCT04760860` - Terazosin for Dementia With Lewy Bodies	Phase 1/Phase 2
Terminated	`NCT02928445` - Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension	Phase 2/Phase 3
Completed	`NCT02910102` - Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia	Phase 2
Terminated	`NCT02871427` - Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder	Phase 2
Completed	`NCT05188105` - Alpha tACS in Dementia With Lewy Bodies	N/A
Active, not recruiting	`NCT04167813` - Trial of Ondansetron as a Parkinson's HAllucinations Treatment	Phase 2
Enrolling by invitation	`NCT04954183` - Development of an EEG Diagnostic for Alzheimer's Disease
Recruiting	`NCT05326750` - Non-invasive Neurostimulation as a Tool for Diagnostics and Management for Neurodegenerative Diseases	N/A
Completed	`NCT01023672` - "Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"	Phase 4
Completed	`NCT03907748` - Home-based Family Caregiver-delivered Music and Reading Interventions for People With Dementia	N/A
Completed	`NCT04649164` - Learning to PERSEVERE: Peer Mentor Support and Caregiver Education in Lewy Body Dementia	N/A
Recruiting	`NCT03924414` - Trial of Parkinson's And Zoledronic Acid	Phase 4
Completed	`NCT05885620` - SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms